Xiuning Le: Personalized Care for EGFR-mutant NSCLC
Xiuning Le, Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, shared a post on LinkedIn about recent paper she and colleagues co-authored, published in CA: A Cancer Journal for Clinicians.
“New Online: ‘Personalized Care for EGFR-mutant NSCLC’ at CA: A Cancer Journal for Clinicians. American Cancer Society Journals.
We Alfredo Addeo, Jill Feldman, Jair Bar, Kaushal Parikh, Timothée Olivier comprehensively reviewed:
- EGFR classification and its impact on future drug development
- All the major EGFR trials: from IPASS to FLAURA2, MARIPOSA to ARTEMIS, as well as ADUARA and LAURA.
- Most importantly, known clinical and molecular poor prognostic factors to guide personalized selection of therapies.
- CA: A Cancer Journal for Clinicians is the flagship clinical oncology journal of the American Cancer Society, with impact factor above 500, consistently ranked number 1 out of all oncology journals. Cited mostly for cancer statistics and clinical reviews and guidelines.”
Title: Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management
Authors: Maxime Borgeaud, Timothée Olivier, Jair Bar, Stephanie Pei Li Saw, Kaushal Parikh, Giuseppe Luigi Banna, Claudio De Vito, Jill Feldman, Xiuning Le, Alfredo Addeo
Read The Full Article at CA: A Cancer Journal for Clinicians.
More posts featuring Xiuning Le.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023